Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by investment analysts at Laurentian Bank of Canada from a “buy” rating to a “speculative buy” rating in a research report issued to clients and investors on Friday.

A number of other equities analysts have also issued reports on SYN. Zacks Investment Research lowered shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 1st. FBR & Co reissued a “buy” rating on shares of Synthetic Biologics in a research report on Friday, August 5th. Griffin Securities set a $5.80 price target on shares of Synthetic Biologics and gave the stock a “buy” rating in a research report on Wednesday, August 31st. Finally, BTIG Research initiated coverage on shares of Synthetic Biologics in a research report on Thursday, August 25th. They set a “buy” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Synthetic Biologics has an average rating of “Buy” and an average price target of $5.41.

Analyst Recommendations for Synthetic Biologics (NYSEMKT:SYN)

Synthetic Biologics (NYSEMKT:SYN) traded up 1.2302% during trading on Friday, hitting $0.8805. 464,842 shares of the stock traded hands. Synthetic Biologics has a 52-week low of $0.82 and a 52-week high of $3.09. The stock has a 50 day moving average price of $1.39 and a 200-day moving average price of $1.70. The stock’s market cap is $81.16 million.

Synthetic Biologics (NYSEMKT:SYN) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. On average, analysts anticipate that Synthetic Biologics will post ($0.35) EPS for the current fiscal year.

An institutional investor recently raised its position in Synthetic Biologics stock. UBS Group AG boosted its position in shares of Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned about 0.32% of Synthetic Biologics worth $680,000 at the end of the most recent reporting period.

COPYRIGHT VIOLATION NOTICE: “Synthetic Biologics Inc (SYN) Downgraded by Laurentian Bank of Canada” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The correct version of this piece can be read at

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.